Hepatorenal syndrome: Beyond liver failure

AACN Advanced Critical Care

Volumn 21, Issue 2, 2010, Pages 165-184

  Fisher, Elaine M ^a   Brown, Diane K ^a  

^a UNIVERSITY OF AKRON   (United States)

Author keywords

Ascites; Circulation; Hepatorenal syndrome; Liver cirrhosis; Nursing

Indexed keywords

ARTICLE; CONTINUING EDUCATION; HEPATORENAL SYNDROME; HUMAN; PATHOPHYSIOLOGY;

EDUCATION, CONTINUING; HEPATORENAL SYNDROME; HUMANS;

EID: 77951988186     PISSN: 15597768     EISSN: 15597768     Source Type: Journal    
DOI: 10.1097/NCI.0b013e3181d9261b     Document Type: Article

References (67)

1. Centers for Disease Control and Prevention. National vital statistics report. http://www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57-14.pdf. Accessed April 5, 2010.
2. Flint A. Clinical report on hydro-peritoneum based on an analysis of forty-six cases. Am J Med Sci. 1863; 45: 306-339.
3. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993; 105: 229-236.
4. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006; 74: 756-762.
5. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol. 2001; 35: 195-199.
6. Hernandez-Guerra M, Garcia-Pagan JC, Turnes J, et al. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology. 2006; 43: 485-491.
7. Gentilini P, Laffi G, La Villa G, Romanelli RG, Blendis LM. Ascites and hepatorenal syndrome during cirrhosis: two entities or the continuation of the same complication? J Hepatol. 1999; 31: 1088-1097.
8. Gines P, Arroyo V, Rodes J, Schrier R. Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. 2nd ed. Malden, MA: Blackwell Publication; 2005.
9. Martin P Y, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med. 1998; 339: 533-541.
10. Lluch P, Torondel B, Medina P, et al. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol. 2004; 41: 55-59.
11. Lieberman FL, Reynolds TB. Plasma volume in cirrhosis of the liver: its relation of portal hypertension, ascites, and renal failure. J Clin Invest. 1967; 46: 1297-1308.
12. Levy M. Pathogenesis of sodium retention in early cirrhosis of the liver: evidence for vascular overfilling. Semin Liver Dis. 1994; 14: 4-13.
13. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005; 42: 439-447.
14. Esteva-Font C, Baccaro M, Fernandez P, Sans L, Guevara M, et al. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology. 2006; 44: 1555-1563.
15. Fitz JG. Hepatorenal syndrome. In: Feldman M, Friedman L, Sleisenger M, eds. Gastrointestinal and Liver Disease: Pathophysiological/Diagnosis/ Management. 7th ed. Philadelphia: Saunders; 2002: 1554-1557.
16. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci (Lond). 2001; 101: 621-628.
17. Iwao T, Oho K, Sakai T, et al. Splanchnic and extrasplanchnic arterial hemodynamics in patients with cirrhosis. J Hepatol. 1997; 27: 817-823.
18. Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis. 2008; 28: 81-95.
19. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996; 23: 164-176.
20. Munoz SJ. The hepatorenal syndrome. Med Clin North Am. 2008; 92: 813-837.
21. Colle I, Durand F, Pessione F, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol. 2002; 17: 882-888.
22. Watt K, Uhanova J, Minuk G Y. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol. 2002; 97: 11046-2050.
23. Marrero J, Martinez FJ, Hyzy R. Advances in critical care hepatology. Am J Respir Crit Care Med. 2003; 168: 1421-1426.
24. Gines A, Salmeron JM, Gines P, et al. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol. 1993; 17: 220-226.
25. Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int. 2006; 26: 834-839.
26. Stewart C, Lucey M. Approach to the patient with chronic liver disease and fulminant hepatic failure. In: Humes H, DuPont H, Griffin J, et al, eds. Kelley's Textbook of Internal Medicine. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 801-804.
27. Murray K F, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005; 41: 1407-1432.
28. Criteria for Child-Pugh classification. http://depts.washington. edu/uwhep/calculations/childspugh.htm. Accessed April 5, 2010.
29. The MELD Model, UNOS Modification. http://www.mayoclinic.org/meld/ mayomodel6.html. Accessed April 5, 2010.
30. Dove LM. Management of hepatitis C after transplantation: a long way from success. Eur J Gastroenterol Hepatol. 2004; 16: 1131-1133.
31. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002; 122: 923-930.
32. Demirtas S, Bozbas A, Akbay A, Yavuz Y, Karaca L. Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Clin Chim Acta. 2001; 311: 81-89.
33. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet. 2003; 362: 1819-1827.
34. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007; 56: 1310-1318. (Pubitemid 47300435)
35. Genzini T, Torricelli F. Hepatorenal syndrome: an update. Sao Paulo Med J. 2007; 125: 50-60.
36. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002; 35: 140-148.
37. Fasolato S, Angeli P, Dallagnese L, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology. 2007; 45: 223-229.
38. Lee JM, Han KH, Ahn SH. Ascites and spontaneous bacterial peritonitis: an Asian perspective. J Gastroenterol Hepatol. 2009; 24: 1494-1503.
39. Moller S, Henriksen J. Neurohumoral fluid regulation in chronic liver disease. Scand J Clin Lab Invest. 1998; 58: 361-372. (Pubitemid 28489465)
40. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007; 56: 1310-1318. (Pubitemid 47300435)
41. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology. 1998; 27: 35-41.
42. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology. 2004; 39: 841-856.
43. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology. 2002; 36: 374-380.
44. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003; 18: 152-156.
45. Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007; 52: 742-748.
46. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002; 36: 941-948.
47. Fevery J, Van Cutsem E, Nevens F, Van Steenbergen W, Verberckmoes R, De Groote J. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol. 1990; 11: 153-158.
48. Clewell JD, Walker-Renard P. Prostaglandins for the treatment of hepatorenal syndrome. Ann Pharmacother. 1994; 28: 54-55.
49. Wilson JR. Dopamine in the hepatorenal syndrome. JAMA. 1977; 238: 2719-2720.
50. Wong L P, Blackley M P, Andreoni KA, Chin H, Falk RJ, Klemmer PJ. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int. 2005; 68: 362-370.
51. McCormick P, Donnelly C. Management of hepatorenal syndrome. Pharmacol Ther. 2008; 119: 1-6.
52. Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000; 47: 288-295.
53. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients. Transplantation. 1991; 51: 428-430.
54. Marik PE, Wood K, Starzl TE. The course of type 1 hepatorenal syndrome post liver transplantation. Nephrol Dial Transpl. 2006; 21: 478-482.
55. Ruiz R, Kunitake H, Wilkinson AH, et al. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg. 2006; 141: 735-741.
56. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology. 2003; 37: 233-243.
57. Goldenberg I, Shechter M, Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature. Eur Heart J. 2004; 25: 212-218.
58. Epstein M. Renal prostaglandins and the control of renal function in liver disease. Am J Med. 1986; 80: 46-55.
59. Claria J, Kent JD, Lopez-Parra M, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology. 2005; 41: 579-587.
60. Heidelbaugh JJ, Sherbondy M. Cirrhosis and chronic liver failure: part II. Complications and treatment. Am Fam Physician. 2006; 74: 767-776.
61. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999; 341: 403-409.
62. Park YH, Lee HC, Song HG, et al. Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea. J Gastroenterol Hepatol. 2003; 18: 927-933.
63. Nutritional status in cirrhosis: Italian Multicenter Cooperation Project on Nutrition in Liver Cirrhosis. J Hepatol. 1994; 21: 317-325.
64. Crippin J. Is tube feeding an option in patients with liver disease? Nutr Clin Pract. 2006; 21: 296-298.
65. Mizock BA. Nutritional support in hepatic encephalopathy. Nutrition. 1999; 15: 220-228.
66. Stroud M, Duncan H, Nightingale J. Guidelines for enteral feeding in adult hospital patients. Gut. 2003; 52: vii1-vii12.
67. Moller S, Henriksen J, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int. 2008; 2: 416-428.